Mannkind Corporation (MNKD) Oversold Based on One Indicator

Mark Melin

Published onAugust 1, 2014

Updated on May 13, 2021

As the stock of MannKind Corporation (NASDAQ:MNKD) tumbled Wednesday and Thursday, outpacing general stock market declines, while a Forbes report, citing a technical indicator, says it is oversold and might be time for a bounce back.

Table of Contents

MannKind’s new wonder drug is a dud: Tourbillon

MannKind Corporation (NASDAQ:MNKD) had been the subject of short speculation from the hedge fund Tourbillon Capital Partners, first reported by CNBC July 25. Tourbillon had charged that Mannkind's new wonder drug, considered a cause for the recent dramatic rise in the stock price, is really a dud due to health risks and pricing issues.

Mannkind was trading just above $6 per...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Mannkind Corporation (MNKD) Oversold Based on One Indicator

MannKind’s new wonder drug is a dud: Tourbillon

Login required to continue reading.

Get Your Business News